Patients with high expression of TPST2 demonstrated poorer prognosis compared to patients with low expression of TPST2 in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), ovarian serous cystadenocarcinoma (OV), sarcoma (SARC), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) (Fig. 6c). This evidence concerns the gene TPST2 and sarcoma.